


Stabilis



Aminophylline



Товарное название

Aminocardol	Турция
Aminodic	Иран
Aminofilina	Аргентина, Венесуэла, Италия, Колумбия, Мексика, Перу, Португалия, чили, Эквадор
Aminomal	Италия
Aminophyllin	Малайзия, Норвегия, Швейцария
Aminophylline	Австралия, Великобритания, Греция, Иран, Ирландия, Канада, Малайзия, Саудовская Аравия, Соединённые Штаты Америки
Aminophyllinum	Польша
Amipine	Малайзия
Amofilin	Колумбия, Мексика
Broncophilina	Венесуэла
Diaphyllin	Венгрия
Drafilyn	Мексика
Euphyllin	Австрия, Голландия, Люксембург, Саудовская Аравия, Швейцария
Euphyllina	Италия
Fadafilina	Аргентина
Minophyline	Египет
Minotec	Мексика
Miofilin	Румыния
Neophyllin	Япония
Tecar	Турция
Tefamin	Италия
Teofillina	Италия
Teofylamin	Дания
Teofyllamin	Швеция
Teolin	Иран



Стабильность растворов

PVC		1,3 mg/ml	25°C		48			434
PVC		1,3 mg/ml	4°C		48			434
PVC		0,5 mg/ml	25°C		48			539

PVC		1,3 mg/ml	25°C		48			434
PVC		1,3 mg/ml	4°C		48			434
PP		5 mg/ml	22°C		91			478
PP		5 mg/ml	4°C		91			478



Стабильность смесей

		1 & 2 mg/ml	22°C		Cefuroxime sodium : 7,5 & 15 mg/ml	4		96
		1 & 2 mg/ml	24°C		Fluconazole : 0,5 & 1,5 mg/ml	3		262
		2 mg/ml	25°C		Ceftazidime : 40 mg/ml	2		900
		1 & 2 mg/ml	22°C		Cefuroxime sodium : 7,5 & 15 mg/ml	4		96
		1 & 2 mg/ml	24°C		Fluconazole : 0,5 & 1,5 mg/ml	3		262
		2 mg/ml	25°C		Ceftazidime : 40 mg/ml	2		900
		1 & 2 mg/ml	22°C		Cefuroxime sodium : 7,5 & 15 mg/ml	4		96
		1 & 2 mg/ml	22°C		Cefuroxime sodium : 7,5 & 15 mg/ml	4		96
PVC		0,5 & 2 mg/ml	?		Ranitidine hydrochloride : 0,05 & 2 mg/ml	48		210
PVC		2 mg/ml	23°C		Flumazenil : 0,02 mg/ml	24		187
PVC		0,5 mg/ml	25°C		Cimetidine hydrochloride : 1,2 mg/ml	48		539
PVC		0,5 & 2 mg/ml	?		Ranitidine hydrochloride : 0,05 & 2 mg/ml	48		210



Факторы, которые влияют на стабильность

				316
--	--	--	--	-----



Совместимость

	Aminophylline : 2.5 mg/ml Allopurinol sodium : 3 mg/ml	307
	Aminophylline : 5 mg/ml Amiodarone hydrochloride : 4 mg/ml	1036
	Aminophylline : 5 mg/ml Amiodarone hydrochloride : 4 mg/ml	1036
	Aminophylline Ascorbic acid	5089

	Aminophylline : 1 mg/ml Atracurium besylate : 0.5 mg/ml		402
	Aminophylline : 2.5 mg/ml Bivalirudin : 5 mg/ml		1713
	Aminophylline		434
	Aminophylline : 2.5 mg/ml Amifostine : 10 mg/ml		3
	Aminophylline : 25 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
	Aminophylline : 2.5 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
	Aminophylline : 2.5 mg/ml Anidulafungin : 0.5 mg/ml		1982
	Aminophylline : 2.5 mg/ml Aztreonam : 40 mg/ml		99
	Aminophylline Bleomycin sulfate		4154
	Aminophylline Bleomycin sulfate		3646
	Aminophylline : 1 mg/ml Bretylum tosilate : 1 mg/ml		1193
	Aminophylline : 1 mg/ml Bretylum tosilate : 1 mg/ml		1193
	Aminophylline Cefepime dihydrochloride		3548
	Aminophylline : 1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
	Aminophylline : 1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
	Aminophylline : 2,5 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
	Aminophylline : 2,5 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
	Aminophylline : 2,5 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
	Aminophylline Ceftazidime		3543
	Aminophylline : 0.16 mg/ml Ceftazidime : 0.32 mg/ml		3696
	Aminophylline : 1 & 2 mg/ml Ceftazidime : 2 & 6 mg/ml		900
	Aminophylline : 1 & 2 mg/ml Ceftazidime : 2 & 6 mg/ml		900
	Aminophylline : 2.5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
	Aminophylline : 2.5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
	Aminophylline : 2.5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
	Aminophylline : 1 & 4 mg/ml Ceftriaxone disodium : 20 & 40 mg/ml		276

		Aminophylline : 1 & 4 mg/ml Ceftriaxone disodium : 20 & 40 mg/ml		276
		Aminophylline : 1 & 2 mg/ml Cefuroxime sodium : 7,5 & 15 mg/ml		96
		Aminophylline : 1 & 2 mg/ml Cefuroxime sodium : 7,5 & 15 mg/ml		96
		Aminophylline : 1 & 2 mg/ml Cefuroxime sodium : 7,5 & 15 mg/ml		96
		Aminophylline : 1 & 2 mg/ml Cefuroxime sodium : 7,5 & 15 mg/ml		96
		Aminophylline : 0,5 mg/ml Cimetidine hydrochloride : 1,2 mg/ml		539
		Aminophylline : 1.2 mg/ml Ciprofloxacin lactate : 1.5 mg/ml		434
		Aminophylline : 2 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Aminophylline : 2 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Aminophylline : 1.2 mg/ml Ciprofloxacin lactate : 1.5 mg/ml		434
		Aminophylline : 2.5 mg/ml Cisatracurium besylate : 0.1 & 2 mg/ml		299
		Aminophylline : 2.5 mg/ml Cisatracurium besylate : 5 mg/ml		299
		Aminophylline : 2.5 mg/ml Cladribine : 0.5 mg/ml		1496
		Aminophylline : 2.5 mg/ml Cladribine : 0.015 mg/ml		1496
		Aminophylline Clindamycin phosphate		3526
		Aminophylline : 0,9 mg/ml Clonidine hydrochloride : 0,018 mg/ml		2018
		Aminophylline : 0,625 mg/ml Dexamethasone sodium phosphate : 0,03 mg/ml		1259
		Aminophylline : 1 mg/ml Dobutamine hydrochloride : 1 mg/ml		1058
		Aminophylline : 25 mg/ml	RL	4603
		Aminophylline Dimenhydrinate		2087
		Aminophylline : 2.5 mg/ml Docetaxel : 0.9 mg/ml		1754
		Aminophylline : 2.5 mg/ml		301
		Aminophylline : 1 mg/ml		939
		Aminophylline : 2 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Aminophylline : 25 mg/ml Diltiazem hydrochloride : 1 mg/ml		198
		Aminophylline : 1 mg/ml Dobutamine hydrochloride : 1 mg/ml		1058
		Aminophylline : 0.25 >> 1.5 mg/ml		1188

		Aminophylline : 2.5 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Aminophylline : 5 & 25 mg/ml		316
		Aminophylline : 5 mg/ml Dobutamine hydrochloride : 2 mg/ml		1041
		Aminophylline : 2.5 mg/ml		1415
		Aminophylline : 25 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Aminophylline : 25 mg/ml Dopamine hydrochloride : 3 mg/ml		3759
		Aminophylline : 2,5 mg/ml Doripenem : 5 mg/ml		2262
		Aminophylline : 2,5 mg/ml Doripenem : 5 mg/ml		2262
		Aminophylline Doxapram hydrochloride		3612
		Aminophylline : 2.5 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Aminophylline : 1 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Aminophylline Erythromycin lactobionate		3674
		Aminophylline : 1 mg/ml Esmolol hydrochloride : 6 mg/ml		174
		Aminophylline : 1 mg/ml Esmolol hydrochloride : 10 mg/ml		384
		Aminophylline : 2.5 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Aminophylline : 2.5 mg/ml Famotidine : 2 mg/ml		215
		Aminophylline : 2,5 mg/ml Famotidine		397
		Aminophylline : 2.5 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Aminophylline : 2.5 mg/ml Filgrastim : 30 µg/ml		244
		Aminophylline : 1 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Aminophylline : 1 & 2 mg/ml Fluconazole : 0.5 & 1.5 mg/ml		262
		Aminophylline : 1 & 2 mg/ml Fluconazole : 0.5 & 1.5 mg/ml		262
		Aminophylline : 25 mg/ml Fluconazole : 2 mg/ml		496
		Aminophylline : 2.5 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Aminophylline : 2 mg/ml Flumazenil : 0,02 mg/ml		187
		Aminophylline : 25 mg/ml Foscarnet sodium : 24 mg/ml		73
		Aminophylline : 1 mg/ml Furosemide : 1 mg/ml		1232

		Aminophylline : 25 mg/ml Gallium nitrate : 1 mg/ml		91
		Aminophylline : 2.5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Aminophylline : 2.5 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Aminophylline : 2.5 mg/ml Hetastarch : 60 mg/ml		1721
		Aminophylline : 0,625 mg/ml Hydrocortisone sodium succinate : 0,25 mg/ml		1259
		Aminophylline : 50 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Aminophylline : 25 mg/ml Ketamine hydrochloride : 50 mg/ml		4389
		Aminophylline : 1 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Aminophylline : 2.5 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Aminophylline : 25 mg/ml Levofloxacin : 5 mg/ml		1072
		Aminophylline : 1 mg/ml Lidocaine hydrochloride : 2 mg/ml		619
		Aminophylline : 1 mg/ml Lidocaine hydrochloride : 2 mg/ml	RL	619
		Aminophylline : 1 mg/ml Lidocaine hydrochloride : 2 mg/ml		619
		Aminophylline : 2.5 mg/ml Linezolid : 2 mg/ml		1925
		Aminophylline : 2.5 mg/ml Melfalan : 0.1 mg/ml		169
		Aminophylline : 1 mg/ml Meropenem : 1 & 20 mg/ml		266
		Aminophylline		434
		Aminophylline : 25 mg/ml Meropenem : 1 & 50 mg/ml		266
		Aminophylline Mesna		3602
		Aminophylline : 1 mg/ml Methylprednisolone sodium succinate : 0,5 & 2 mg/ml		390
		Aminophylline : 1 mg/ml Methylprednisolone sodium succinate : 0,5 & 2 mg/ml		390
		Aminophylline : 2.5 mg/ml Micafungin : 1.5 mg/ml		2108
		Aminophylline : 0.72 mg/ml Midazolam hydrochloride : 0.25 & 0.4 mg/ml		1888
		Aminophylline : 0.72 mg/ml Midazolam hydrochloride : 0.05 mg/ml		1888
		Aminophylline Morphine hydrochloride		5069
		Aminophylline Morphine sulfate		3531

		Aminophylline : 50 mg/ml N-acetylcysteine : 200 mg/ml	Ø	3766
		Aminophylline : 50 mg/ml Naloxone hydrochloride : 0.4 mg/ml	Ø	3408
		Aminophylline : 0,8 mg/ml Netilmicin sulfate : 5 mg/ml		1236
		Aminophylline : 1 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Aminophylline : 1 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Aminophylline : 1 mg/ml Nitroglycerin : 0.4 mg/ml		1049
		Aminophylline : 1 mg/ml Nitroglycerin : 0.4 mg/ml		1049
		Aminophylline : 2.5 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Aminophylline : 1 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Aminophylline : 2,5 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Aminophylline : 2.5 mg/ml Paclitaxel : 1.2 mg/ml		248
		Aminophylline : 1 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Aminophylline Pantoprazole sodium		2090
		Aminophylline : 25 mg/ml Paracetamol : 10 mg/ml		4742
		Aminophylline : 2.5 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Aminophylline Pethidine hydrochloride		3525
		Aminophylline : 2.5 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Aminophylline : 25 mg/ml Potassium chloride : 40 mEq/l	RL	730
		Aminophylline : 25 mg/ml Potassium chloride : 40 mEq/l		730
		Aminophylline : 25 mg/ml Potassium chloride : 40 mEq/l		730
		Aminophylline : 2.5 mg/ml Propofol : 10 mg/ml	Ø	300
		Aminophylline : 0.5 & 2 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		210
		Aminophylline : 4 mg/ml Ranitidine hydrochloride : 0,5 mg/ml		396
		Aminophylline : 0.5 & 2 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		214
		Aminophylline : 0.5 & 2 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		210
		Aminophylline : 0.5 & 2 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		214

	Aminophylline : 2.5 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
	Aminophylline : 2.5 mg/ml Sargramostim : 10 µg/ml		335
	Aminophylline : 24 mg/ml Sugammadex : 100 mg/ml		3372
	Aminophylline : 2 mg/ml Tacrolimus : 1000 µg/ml		479
	Aminophylline : 2.5 mg/ml Teniposide : 0.1 mg/ml		905
	Aminophylline : 2.5 mg/ml Thiotepa : 1 mg/ml		249
	Aminophylline Vancomycin hydrochloride		3588
	Aminophylline : 1 mg/ml Vecuronium bromide : 0.1 mg/ml		402
	Aminophylline : 1 mg/ml Verapamil hydrochloride : 0,08 mg/ml		706
	Aminophylline : 1 mg/ml Verapamil hydrochloride : 0,08 mg/ml		706
	Aminophylline : 1 mg/ml Verapamil hydrochloride : 0,1 & 0,4 mg/ml		364
	Aminophylline : 2.5 mg/ml Vinorelbine tartrate : 1 mg/ml		84
	Aminophylline : 4 mg/ml Warfarin sodium : 2 mg/ml		315



Способы введения



Библиография

	ТИП	публикация
3	Журнал	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Журнал	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73	Журнал	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Журнал	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.

84	Журнал	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Журнал	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
96	Журнал	Stewart JT, Warren FW, Johnson SM. Stability of cefuroxime sodium and aminophylline or theophylline. Am J Hosp Pharm 1994 ; 51: 809-811.
99	Журнал	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Журнал	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
174	Журнал	Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO. Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride. Am J Hosp Pharm 1990 ; 47: 1567-1571.
182	Журнал	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
187	Журнал	Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912.
198	Журнал	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
210	Журнал	Stewart JT, Warren FW, King AD. Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994 ; 51: 1802-1807.
214	Журнал	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
215	Журнал	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Журнал	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Журнал	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Журнал	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Журнал	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.

262	Журнал	Johnson CE, Jacobson PA, Pillen HA, Woycik CL. Stability and compatibility of fluconazole and aminophylline in intravenous admixtures. Am J Hosp Pharm 1993 ; 50: 703-706.
266	Журнал	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
276	Журнал	Parrish MA, Bailey LC, Medwick T. Stability of ceftriaxone sodium and aminophylline or theophylline in intravenous admixtures. Am J Hosp Pharm 1994 ; 51: 92-94.
288	Журнал	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
299	Журнал	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Журнал	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Журнал	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Журнал	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
315	Журнал	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316	Журнал	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
334	Журнал	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Журнал	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
364	Журнал	Johnson CE, Lloyd CW, Mesaros JL, Rubley GJ. Compatibility of aminophylline and verapamil in intravenous admixtures. Am J Hosp Pharm 1989 ; 46: 97-100.
384	Журнал	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	Журнал	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
390	Журнал	Johnson CE, Cohen IA, Craft DA, Lizer MH. Compatibility of aminophylline and methylprednisolone sodium succinate intravenous admixtures. Am J Hosp Pharm 1986 ; 43: 1482-1485.

396	Журнал	Chilvers MR, Lysne JM. Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications. Am J Hosp Pharm 1989 ; 46: 2057-2058.
397	Журнал	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
402	Журнал	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
434	Журнал	Goodwin SD, Nix DE, Heyd A, Wilton JH. Compatibility of ciprofloxacin injection with selected drugs and solutions. Am J Hosp Pharm 1991 ; 48: 2166-2171.
478	Журнал	Nahata MC, Morosco RS, Hipple TF. Stability of aminophylline in bacteriostatic water for injection stored in plastic syringes at two temperatures. Am J Hosp Pharm 1992 ; 49: 2962-2963.
479	Журнал	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Журнал	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Журнал	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
539	Журнал	Baptista RJ, Mitrano FP. Stability and compatibility of cimetidine hydrochloride and aminophylline in dextrose 5% in water injection. Drug Intell Clin Pharm 1988 ; 22: 592-593.
619	Журнал	Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives. Am J Hosp Pharm 1982 ; 39: 1013-1015.
706	Журнал	Cutie MR. Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1981 ; 38: 231.
730	Журнал	Allen LV, Saul Levinson R, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943.
900	Журнал	Pleasants RA, Vaughan LM, Williams DM, Fox JL. Compatibility of ceftazidime and aminophylline admixtures for different methods of intravenous infusion. Ann Pharmacotherapy 1992 ; 26: 1221-1226.
905	Журнал	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Журнал	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Журнал	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.

1036	Журнал	Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041	Журнал	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1049	Журнал	Klamerus KJ, Ueda CT, Newton DW. Stability of nitroglycerin in intravenous admixtures. Am J Hosp Pharm 1984 ; 41: 303-305.
1058	Журнал	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1072	Журнал	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1188	Журнал	Niemiec PW, Venderveen TW, Hohenwarter MW, Gadsden RH. Stability of aminophylline injection in three parenteral nutrient solutions. Am J Hosp Pharm 1983 ; 40: 428-432.
1193	Журнал	Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ. Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives. Am J Hosp Pharm 1983 ; 40: 1010-1012.
1232	Журнал	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1236	Журнал	Kuhn RJ, Nahata MC. Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline. Am J Hosp Pharm 1986 ; 43: 1241-1242.
1259	Журнал	Jhunjhunwala VP, Bhalla HL. Compatibility of aminophylline with hydrocortisone sodium succinate or dexamethasone sodium phosphate in 5% dextrose injection. Am J Hosp Pharm 1981 ; 38: 900-901.
1315	Журнал	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Журнал	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Журнал	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Журнал	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Журнал	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496	Журнал	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Журнал	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.

1662	Журнал	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Журнал	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Журнал	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Журнал	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Журнал	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Журнал	Trissel LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1888	Журнал	Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48.
1925	Журнал	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Журнал	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Журнал	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2018	Журнал	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2087	Журнал	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Журнал	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Журнал	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Журнал	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2262	Журнал	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmore T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Журнал	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.

3152	Журнал	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3249	Журнал	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3372	Журнал	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3408	Журнал	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3525	Лаборатория	Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012
3526	Лаборатория	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3531	Лаборатория	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3543	Лаборатория	Ceftazidime – Summary of Product Characteristics Wockhardt 2013
3548	Лаборатория	Cefepime (Maxipime®) - Summary of Product characteristics. Bristol Myers Squibb 2007
3588	Лаборатория	Vancomycine (Vancocin®) - Résumé des caractéristiques du produit Sandoz 2011
3602	Лаборатория	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3612	Лаборатория	Doxapram (Dopram) - Summary of Product Characteristics Amdipharm Mercury Company 2012
3646	Лаборатория	Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produit Sanofi Aventis France 2013
3674	Лаборатория	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3696	Журнал	Santos C.A.D, Oliveira-Nascimento L, Knirsch M.C, Stephano M.A, Pessoa J?nior A, Penna T.C.V. Biological and physicochemical stability of ceftazidime and aminophylline on glucose parenteral solution. Braz J Pharm Sci 2012 ; 48, 4: 691-698.
3759	Журнал	Igarashi K, Kawahara M. Examination of the cause of changing solution color by mixing aminophylline and dopamine, the compatibility of which was indicated by the supplier. Yakugaku Zasshi 2014 ; 134, 2: 293-298.
3766	Журнал	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3824	Журнал	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
4154	Лаборатория	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4389	Журнал	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisentan et la kétamine. Pharmactuel 2019 ;52,4:206-213

4528	Журнал	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Журнал	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Журнал	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
5069	Лаборатория	MORPHINE (CHLORHYDRATE) AGUETTANT 10 mg/mL, solution injectable - Résumé des caractéristiques du produit. LABORATOIRE AGUETTANT 2024
5089	Лаборатория	Ascorbic Acid Injection 500mg/5ml - Summary of Product Characteristics Updated 04-Jan-2024 Phoenix Labs Phoenix Labs 2024



Словарь

	Разное		Инъекция
	Товарное название		Стабильность растворов
	Упаковка		Молекула Molekula
	Концентрация		Температура
	Хранение		Продолжительность стабильности
	биоподобие		противоречивые данные
	Ссылки		Поливинилхлорид
	Натрия хлорид 0,9%		Свет
	Час		Защищён от света
	Глюкоза 5%		Шприц полипропилен
	Вода для инъекций + антибактериальны		Не указано
	День		Стабильность смесей
	Растворитель		Молекула
	Стекло		Натрия хлорид 0,45%
	NaCl 0,45% Глюкоза 5%		Факторы, которые влияют на стабильность
	Парентеральное питание (бинарная сме		Стимулирует
	Деградация		Совместимость
	совместимый		Осадки через 15 часов
	несовместимый		Неопределенная несовместимость
	Субвизуальная несовместимость	RL	Раствор Рингера лактата
	Химическая нестабильность		Осадки через 4 часа
	Мутность за один час		NaCl 0,9% + антибактериальный
	Мутность за 4 часа		Немедленные осадки
	Осадки через 12 часов		Парентеральное питание (с липидами)
	Немедленная мутность		Смена цвета через 2 часа
	Нет		Конкретные растворителя
	Осадки через 1 час		Способы введения
	Интравенный, внутривенный		Интравенная, внутривенная инфузия
	Библиография		Словарь